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Functional role of ICAM-3 
polymorphism in genetic susceptibility 
to SARS infection
Key Messages
1. Severe acute respiratory syndrome 
(SARS) patients who are homozygous 
for intercellular adhesion molecule-3 
(ICAM-3) Gly143 showed significant 
association with higher lactate 
dehydrogenase levels and lower total 
white blood cell counts on admission.
2. In vitro functional studies demonstrated 
low level binding of ICAM-3 to DC-SIGN 
and a wide variation in T-cell response of 
the wild-type ICAM-3 genotype.
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Introduction
Genetic polymorphisms are associated with vulnerability to a variety of human 
infections. Association between susceptibility to severe acute respiratory 
syndrome (SARS) and major histocompatibility complex (MHC) class I has 
been reported.1 Clinical outcome of SARS patients vary; only a small proportion 
needed intubation or intensive care. Moreover, immunopathological damage 
rather than uncontrolled viral replication may correlate with clinical progression 
of the disease beyond the first week. 
 Dendritic cells (DCs) are crucial in the defence against pathogens. The dendritic 
cell–specific intercellular adhesion molecule-3 (ICAM-3) grabbing non-integrin 
(DC-SIGN) is a mannose binding lectin expressed on the surface of DCs. The 
ICAM-3 is the natural ligand for DC-SIGN. Expressed constitutively on T-cells, 
ICAM-3 is a potent signalling molecule and major ligand in the initiation of T-
cell–mediated immune response.2 The interaction of adhesion molecules between 
antigen-presenting cells and T-cells is critical for activating antigen-specific T-
cells. The binding between ICAM-3 and its ligands provides transient engagement 
of naive T-cells with DCs, which then allow the T-cells to sample large numbers 
of MHC molecules for the presence of specific peptides.3 This initial cell-to-
cell engagement step is critical for induction of T-cell responses, which play a 
central role in the immuno-regulation of infectious diseases. We hypothesised that 
polymorphisms of ICAM-3 may also influence susceptibility to SARS infection. 
Aims
1. To determine whether ICAM-3 Asp143Gly polymorphism associates with 
susceptibility of SARS infection and its relation to clinicopathological 
outcome of SARS patients.
2. To investigate the role of ICAM-3 polymorphism influencing DC-SIGN-ICAM-3 
interaction and immune response in SARS infection using functional studies.
Methods
This study was conducted from January 2006 to December 2007. A case-control 
genetic association study was performed to examine the contribution of ICAM-3 
Asp143Gly polymorphism to SARS infection and/or any association with the 
clinicopathological outcome of SARS patients. A total of 817 SARS patients 
confirmed by serology and/or real-time polymerase chain reaction were recruited 
from follow-up outpatient clinics of the Pamela Youde Nethersole, Princess 
Margaret, United Christian, Queen Mary, Alice Ho Miu Ling Nethersole, and 
Prince of Wales hospitals. The controls included (1) 260 patients from the general 
outpatient clinics seen at least 2 months after the SARS outbreak, with no clinical 
history, signs or symptoms of inflammation/infection; (2) 307 health care workers 
who had worked in SARS wards but were disease-free and sero-negative for 
SARS; (3) 309 household contacts of SARS patients that remained unaffected and 
sero-negative for SARS. To prevent genotype and allele frequency distribution 
bias, family members of the same household who were genetically related were 
taken into consideration in the statistical analysis of genotypes. All control subjects 
were Hong Kong Chinese. 
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Main outcome measures
The clinical data of the SARS patients were retrospectively 
obtained from Hospital Authority, with the permission of all 
attending clinicians. Data collected include: age, sex, length 
of hospital stay, treatment in intensive care unit, and whether 
patients received assisted ventilation, steroid treatment, pulse 
steroids or intravenous immunoglobulin, and final outcome of 
patients (survival and death). Results of haematological and 
biochemical laboratory investigations on admission included 
the haemoglobin level, absolute lymphocyte count, platelet 
count, white blood cell (WBC) count, and biochemical indices 
(serum/plasma alanine aminotranseferase, albumin, globulin, 
creatinine kinase, lactate dehydrogenase [LDH], urea, sodium, 
potassium and serum creatinine). 
Study instruments
Genotyping of the ICAM-3 polymorphism
Genotyping of the initial SARS patients and health care 
workers was performed using Sequenom MassARRAY 
(Sequenom Inc, San Diego, CA, USA). Genotyping of the 
additional SARS patients, household contacts and outpatient 
controls for the ICAM-3 Gly143 SNP was performed by 
Allelic Discrimination TaqMan Assay (Applied Biosystems 
Inc, Foster City, CA, USA). Appropriate controls and 
replicates were included for quality control.
Production of wild-type and polymorphic variant 
ICAM-3 protein
The coding sequences of ICAM-3 containing Asp143 
and Gly143 allele were separately cloned and then stably 
transfected into 293 cell lines. The stable transfectants 
thus expressed a fusion protein containing the ICAM-3 of 
known genotype. The secreted soluble protein was purified 
and concentrated for in vitro binding studies.
Culturing monocyte-derived dendritic cells
Peripheral blood mononuclear cells (PBMCs) were isolated 
from buffy coat samples obtained from the Hong Kong Red 
Cross Blood Transfusion Service. CD14+ monocytes were 
isolated from PBMCs, from which DCs were induced, using 
MACS separation (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany). These CD14+ cells were cultured in the presence of 
50 ng/ml GM-CSF and 10 ng/ml IL-4. The cells were harvested 
at the 6th day and analysed by flow cytometry.
ICAM-3 binding assay
To investigate the binding affinity of soluble wild-type ICAM-
3 (Asp143) with DC-SIGN transfectants, a stable DC-SIGN 
transfectant was used whereas parental 293 cell line was 
used as negative control. These cells were treated with (1) 
recombinant human ICAM-3 protein (R&D Systems Inc, MN, 
USA, Cat No 715-IC), (2) purified ICAM-3 protein containing 
Asp143, or (3) purified ICAM-3 protein containing Gly143. 
Cells not treated with ICAM-3 protein were used as reference. 
After incubation at 4ºC for 40 min, the treated cells were 
washed twice to remove unbound ICAM-3 proteins, and then 
stained by FITC-labelled anti-ICAM-3 antibody for analysis 
by BD FACSCalibur flow cytometer (BD Biosciences, San 
Jose, CA, USA). Cells not treated with ICAM-3 but stained by 
anti-ICAM-3 antibody were used as reference. To investigate 
the binding affinity of soluble wild-type ICAM-3 with 
DC-SIGN expressed on monocyte-derived DCs, similar 
procedures were performed, except that male human serum 
of AB blood type was included in the binding buffer to 
reduce non-specific binding by blocking the Fc receptors 
known to be present on DCs.
T-cell response
Convalescent SARS patients with the homozygous wild-
type, heterozygous, and homozygous variant genotypes were 
identified. Those who were HLA-A2 positive were re-contacted 
to donate further blood samples for study. Isolated PBMCs 
were used for T-cell response analysis using ELISPOT assay.
Statistical analysis
For the risk association analysis, genotype distributions of the 
patient and control groups were assessed by !2 test. Odds ratio 
(OR) and 95% confidence intervals (CI) were used to measure 
the strength of association. Genotyping results were checked 
for Hardy-Weinburg equilibrium. As a significant proportion 
of the household contacts recruited were genetically related 
with each other, logistic regression with the cluster and 
robust methods (STATA program, College Station, TX, USA) 
was used to factor in genetic relations. For in vitro studies, 
statistical significance was calculated using Student’s t-test. 
For analysis for association with clinical outcome, the !2 
test was used to test for possible association with nominal 
clinical outcome measures. For analysis of numerical 
variables, each parameter was first analysed by Student’s 
t test. Parameters that were significantly different were 
further studied using the !2 test. 
RESULTS
Genetic association study
The demographics of the SARS patients, control groups, 
and their clinical features are summarised in Table 1. The 
genotype and allele frequencies of ICAM-3 Asp143Gly 
SNP of the 817 SARS patients, 260 outpatient controls, 
and 309 household contacts were in Hardy-Weinberg 
equilibrium. As the genotype distribution of the health care 
workers was not in Hardy-Weinberg equilibrium, this group 
was excluded from risk association analysis. No significant 
difference in genotype or allele frequency distribution was 
found when comparing these 2 control groups with SARS 
patients (data not shown). This lack of risk association 
was confirmed even with blood relationship taken into 
account, either by excluding patients who were blood 
relatives or by using logistic regression model analysis. 
Among clinical outcome measures, Student’s t test showed 
significant association for LDH levels on admission (P=0.036) 
and for WBC counts (P=0.036) when comparing homozygous 
wild-type Asp versus homozygous Gly (Fig). The LDH 
levels and WBC counts were divided into high- and low-level 
groups, and the !2 test performed. For LDH levels, the overall 
genotype yielded a P value of 0.015; homozygous Gly versus 
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homozygous Asp (P=0.007, OR=4.31, 95% CI=1.37-13.56). 
Allelic association was observed (P=0.0093, OR=1.75, 95% 
CI=1.14-2.67, Table 2a). Association for WBC counts was also 
demonstrated for homozygous Gly versus homozygous Asp 
(P=0.022, OR=0.30, 95% CI=0.10-0.89, Table 2b). Notably, 
the homozygous Gly genotype associated with higher LDH 
levels and lower WBC counts. No significant association was 
found for nominal clinical outcome measures.
Functional studies 
Using DC-SIGN transfectants, binding experiments showed 
that ICAM-3 protein did bind to DC-SIGN but at a low 
level; at most binding was 15%. Similar binding was also 
shown in the soluble ICAM-3 produced and purified in our 
laboratory, expressing either wild-type Asp143 genotype 
or variant ICAM-3 Gly143 genotype (data not shown). 
Binding experiments using DC-SIGN expressed on DCs 
did not demonstrate ICAM-3 binding to DC-SIGN. Blood 
samples from a total of 15 convalescent SARS-infected 
individuals with different ICAM-3 genotypes and HLA-A2 
positive were retrieved. T-cells harvested from these samples 
were incubated overnight with IL-2 before stimulation by 
SARS peptide and measured for IFN-". Results showed a wide 
range of response for the wild-type genotype, but with no 
significant difference in T-cell responses between the wild-
type and variant genotypes (data not shown).
Discussion
In this large genetic association study for SARS 
susceptibility, no significant risk association was found 
for SARS infection for the ICAM-3 Asp143Gly SNP. 
Nonetheless, genotype analysis of our 817 SARS patients 
showed significant association of higher LDH levels and 
lower WBC counts in SARS patients on admission with the 
homozygous Gly143 genotype of ICAM-3, which supports 
the role of ICAM-3 in the immunopathogenesis of SARS. 
These findings are in keeping with the role of ICAM-3 in 
T-cell activation and the immune response. As the SARS 
patients were from six different hospitals throughout Hong 
Kong, there may have been confounding factors, such as 
differences in management preferences pertaining to length 
of hospital stay, level of intensive care, and decision to 
initiate assisted ventilation or administer steroids. This 
may have contributed to non-identification of significant 
associations with other clinical parameters. Laboratory 
parameters on the other hand were more standardised. 
 Although the LDH level is a relatively non-specific 
reflection of tissue destruction, the association with higher 
Demographics SARS patients (n=817) Controls
Health care workers (n=307) Household contacts (n=309) Out-patients (n=260)
Mean±SD, median 
(range) age (years)
 40±14, 38 (5-88) 35±10, 33 (21-60) 42±14, 43 (18-80) 50±20, 47 (4-95)
Male:female 2:3 2:6.6 2:2.4 2:4
No. (%) of female 505 (61.8) 235 (76.5) 168 (54.4) 173 (66.5)
Table 1a. Demographics of severe acute respiratory syndrome (SARS) patients and controls
Characteristics No. (%) of SARS 
patients
Treated in intensive care unit (ICU) 136 (16.6)
Received assisted ventilation 76 (9.3)
Received steroid treatment 795 (97.3)
Received pulse steroid/intravenous 
immunoglobulin
517 (63.3)
Mean±SD, median (range) length of 
hospital stay (days)
28.2±17.9, 23 (4-235)
Death 12 (1.5)
Mean±SD, Median (range) of length of 
ICU stay (days)
2.7±10.8, 0 (0-139)
Table 1b. Characteristics of severe acute respiratory syndrome 
(SARS) patients
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Fig. Genotype frequencies of intercellular adhesion molecule-3 (ICAM-3) of all severe acute respiratory syndrome (SARS) 
patients: (a) normalised lactate dehydrogenase (LDH) levels on admission (as ratio to the upper limit of the normal reference 
range) (b) white blood cell (WBC) counts on admission (copyright 2007 Journal of Infectious Diseases) 
* TT denotes homozygous Asp143, CT heterozygous Gly/Asp, and CC homozygous Gly143
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LDH levels and lower WBC counts in SARS patients suggests 
immune response–associated leukocyte destruction. Indeed 
high peak LDH levels have been reported to be independent 
predictors of adverse outcome.4 Thus SARS patients who 
are homozygous for Gly 143 genotype of the ICAM-3 
Asp143Gly SNP have a four-fold chance of higher LDH 
levels on admission and a poorer prognosis. This may have 
implications for other infectious diseases in which viral-
induced cell death and/or immune responses contribute 
significantly to outcome. Thus, by knowing the genotype 
of the patient, we might be able to predict clinical outcome 
and offer suitable treatment in advance.
 Using DC-SIGN transfectants, in vitro ICAM-3 binding 
experiments demonstrated low levels of soluble ICAM-
3 binding to DC-SIGN, in keeping with previous reports 
suggesting binding between ICAM-3 with DC-SIGN might 
be transient, allowing T-cells to sample large numbers 
of MHC molecules for the presence of specific peptides. 
Our method of detection was thus not sensitive enough 
to demonstrate significant differences in binding affinity 
between the two different genotypes. Although binding 
levels may be low, in vivo they may be sufficient for 
transient interactions between DCs and T-cells. 
 A wide variation in T-cell response suggested that at 
least for wild-type ICAM-3, other factors also affect the 
response. The DCs might transfer SARS coronavirus to 
other cells through DC-SIGN, with interactions between 
ICAM-3 No. (%) of SARS patients Odds ratio (95% CI) P value†
Lower WBC counts* Higher WBC counts*
Genotype n=246 n=569  
TT (Asp) 186 (75.6) 459 (80.7) Reference 0.047
CT (GlyAsp) 52 (21.1) 104 (18.3) - 0.270
CC (Gly) 8 (3.3) 6 (1.0) 0.30 (0.10-0.89) 0.022
C-carrier (Gly-carrier) [CT and CC] 60 (24.4) 110 (19.3) - 0.102
Allele n=492 n=1138  
T (Asp) 424 (86.2) 1022 (89.8) Reference -
C (Gly) 68 (13.8) 116 (10.2) 0.71 (0.51-0.98) 0.034
Table 2b. Genotype and allele analysis of the intercellular adhesion molecule-3 (ICAM-3) Asp143Gly, with white blood cell (WBC) 
counts of all severe acute respiratory syndrome (SARS) patients
* The cutoff value of WBC counts on admission is 4.5
† !2 test for overall genotype
ICAM-3 No. (%) of SARS patients Odds ratio (95% CI) P value† 
Lower LDH levels* Higher LDH levels*
Genotype n=582 n=95  
TT (Asp) 469 (80.6) 68 (71.6) Reference 0.015
CT (GlyAsp) 105 (18) 22 (23.2) - 0.168
CC (Gly) 8 (1.4) 5 (5.2) 4.31 (1.37-13.56) 0.007
C-carrier (Gly-carrier) [CT and CC] 113 (19.4) 27 (28.4) 1.65 (1.009-2.69) 0.044
Allele n=1164 n=190  
T (Asp) 1043 (89.6) 158 (83.2) Reference -
C (Gly) 121 (10.4) 32 (16.8) 1.75 (1.14-2.67) 0.009
* The cutoff value of normalised LDH levels on admission is 1.6
† !2 test for overall genotype
Table 2a. Genotype and allele analysis of the intercellular adhesion molecule-3 (ICAM-3) Asp143Gly, with lactate dehydrogenase 
(LDH) levels on admission of all severe acute respiratory syndrome (SARS) patients
ICAM-3 and DC-SIGN contributing to trans-infection from 
DCs to T cells. Thus the higher LDH levels and lower WBC 
counts associated with homozygous Gly143 genotype could 
also be attributed in part by viral-induced cell death. 
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